Market's view on Uniphar
Published on April 2024
- Uniphar plc is considered a diversified healthcare services company in the UK and Republic of Ireland, operating across three divisions: Commercial & Clinical, Product Access, and Supply Chain & Retail.
- The Commercial & Clinical division provides outsourced sales, marketing, and multichannel account management services to pharmaco-medical manufacturers, along with distribution and support services to medical device manufacturers.
- The Product Access division offers on-demand services, facilitating access to pharmaco-medical products and treatments, and exclusive access services that provide bespoke distribution partnerships for pharmaceutical partners’ key brands.
- The Supply Chain & Retail division handles pre-wholesale and wholesale distribution of pharmaceutical and healthcare products to pharmacies and hospitals.
- Financially, Uniphar’s net profit rose to £48,122m from £27,811m, with a profit growth of 26.3%, trading ahead of expectations. Despite this, the company is considered undervalued with a P/E ratio of 16.9, which is below the healthcare sector P/E ratio of 26.3.
- There is an anticipation of a surge in Uniphar’s value, supported by robust EPS growth of 16.2% and an attractive P/B ratio of 4.08.
- Uniphar has applied to the London Stock Exchange to change the currency in which the company’s ordinary shares are traded from Euro to Sterling, expected to be effective from 1 February 2021.
- Uniphar is also looking to expand into North America and Europe.